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ABSTRACT 
Purpose: To examine the prevalence and clinical correlates of fatigue as an adverse event 
(AE) of antiepileptic drug (AED) treatment in patients with epilepsy. 
Methods: Data from 443 adult outpatients with epilepsy assessed with the Adverse Event 
Profile (AEP) and the Neurological Disorder Depression Inventory for Epilepsy (NDDIE) 
were analysed. 
Results: Fatigue is reported by 36.6% of patients as always a problem during AED treatment. 
Fatigue is more likely to be reported by females (64.8% vs. 35.2%; Chi-Square=16.762; 
df=3; p=0.001) and during treatment with levetiracetam (42.3% vs. 33.2%; Chi-
Square=11.462; df=3; p=0.009). The associations with the female gender and levetiracetam 
treatment were not mediated by depression, as identified with the NDDIE, and could not be 
simply explained by the large number of subjects on levetiracetam treatment, as analogous 
figures resulted from the analysis of a monotherapy subsample (41.7% vs. 30.3%; Chi-
Square=11.547; df = 3; p=0.009).   
Conclusions: One third of patients with epilepsy reports fatigue as a significant problem 
during AED treatment. Fatigue is more likely to be reported by females and seems to be 
specifically associated with LEV treatment. However, fatigue is not mediated by a negative 
effect of LEV on mood. 
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1. INTRODUCTION 
Adverse events (AEs) represent an important cause of treatment failure not only for 
early treatment discontinuation but also because they can preclude fully effective doses [1]. 
In addition, AEs have a negative impact on adherence to treatment [2] and quality of life [3] 
and represent a potential cause of disability and increased health care costs [4].  
Data on AEs of antiepileptic drugs (AEDs) come from several different sources, from 
controlled clinical trials to open studies or uncontrolled retrospective studies and case reports. 
Some AEs are already expected because considered characteristic of a specific drug class (i.e. 
diplopia or dizziness with sodium channel blockers), while other AEs may become evident 
over time because they are epidemiologically rare (i.e. idiosyncratic reactions) [5] or because 
of increasing awareness amongst clinicians and researchers for a specific type of adverse 
event (i.e behavioural effects of AEDs) [6]. However, in other cases AEs may not be 
immediately evident, unless and until patients are systematically screened for them. In fact, a 
cross-sectional study in adult patients with drug-refractory epilepsy has pointed out that the 
prevalence of AEs is around 36.5% when the assessment is based on spontaneous reporting 
and 95.5% when a validated screening questionnaire is used [7]. Current research has shown 
the importance of identifying patterns of association of AEs, highlighting the need to fully 
explore AEs of AEDs [8]. In fact, studies on AEs of AEDs can contribute to the 
understanding of the mechanisms of action of drugs that may not be immediately evident 
because they are not connected with their primary effect.  
Fatigue is usually described as intense tiredness and can be mediated by peripheral or 
central mechanisms. The former refers to an inability to sustain a specified force output or 
work rate during exercise and originates from the cardiovascular or peripheral nervous 
system [9]. Central fatigue refers to a failure to initiate and/or sustain physical activities 
requiring attention and self-motivation, and originates from the central nervous system. 
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Fatigue is a recognised AE of many drug classes although the underlying mechanism hasn’t 
been fully clarified yet. In oncology, fatigue is a well-known drug-related phenomenon[10], 
occurring in the week after the cytotoxic treatment and progressively declining over the 
subsequent weeks [10,11]. However, fatigue has been reported with drugs other than 
chemotherapy agents, like statins [12] or antibiotics [13].  Data on fatigue during treatment 
with drugs acting on the central nervous system is limited and studies about AEDs are more 
than scarce as discussed by a review paper on this subject [14]. Nevertheless, some authors 
have reported that patients with epilepsy, especially if uncontrolled, have higher scores for 
fatigue than healthy controls [15]. The aim of the present paper is to document the proportion 
of patients reporting fatigue as an AE during AED treatment and whether this is reported by a 
specific subgroup of patients.  
 
2. METHODS 
Data from a consecutive sample of patients with an established diagnosis of epilepsy 
attending the Outpatient Clinics of the Atkinson Morley Regional Neurosciences Centre, St 
George’s University Hospitals NHS Foundation Trust in London, were analysed. As part of 
our routine clinical activity, all patients complete the Neurological Disorder Depression 
Inventory for Epilepsy (NDDIE) [16] and the Adverse Event Profile (AEP)[17][18]. As per 
Research Ethic Committee (REC) advice, research limited to secondary use of anonymized 
information previously collected during standard clinical care is excluded from formal REC 
review. Data storage and management was compliant with the Good Clinical Practice 
statement in accordance to the Declaration of Helsinki.  
The NDDI-E was developed by a US Network of epilepsy specialists and it is a well-known 
clinical instrument for the rapid and objective detection of a major depressive episode in 
patients with epilepsy using a cut off score >=15. It has been found to be a very practical and 
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user-friendly screening instrument in an outpatient setting. The AEP was developed by Gus 
Baker at the Walton Neuroscience Centre in Liverpool and it is a 19-item, self-report 
instrument specifically developed to investigate side effects of AEDs. It is possible to analyse 
the scores of individual symptoms as well as calculate overall symptom score. Each symptom 
is quantified on a four-point Likert scale, with 1 indicating that there was “never” a problem; 
2 “rarely” a problem; 3 “sometimes” a problem; 4 “always” problem.  
Fatigue was identified using the specific subscale “Tiredness” of the AEP. Fatigue scores and 
categories were compared for age, gender, age of onset and duration of the disease, epilepsy 
diagnoses, AEDs treatment and combinations, seizure frequency and presence of depression 
as identified with the NDDIE. Frequencies of categorical demographic and clinical variables 
were analysed using the χ2 analysis or Fisher’s exact test. Continuous demographic and 
clinical variables and AEP scores were compared using the Student’s t-test for independent 
samples.  The alpha error was set at 0.05. All statistical analyses were 2-tailed and conducted 
using the Statistical Package for Social Sciences (Version 15 for Windows, SPSS Inc. 
Chicago, IL). 
 
3. RESULTS 
 Demographic and clinical data are shown in Table 1. From a total sample of 443 
patients, 36.6% rated fatigue as “always a problem”, 32.7% “sometimes”, 9% “rarely” and 
21.7% “never”. The mean score +/- SD in the total sample for the fatigue subscale was 2.8 
+/- 1.1.  
Women rated fatigue as “always a problem” more frequently than men (females 64.8% vs. 
males 35.2%; Chi-Square=16.762; df=3; p=0.001). The female gender association was 
further confirmed by the analysis of the fatigue subscale scores in the total sample as females 
presented significantly higher scores than males (males 2.6 +/- 1.2 vs. females 3.0 +/- 1.0; t=-
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3.567; p<0.001). There was no correlation between age and fatigue scores in the two gender 
groups.   
Patients with depression (DEP), as identified with the NDDIE (n=100), presented with higher 
fatigue scores than those without (DEP 3.61 +/- 0.62 vs. NoDEP 2.62 +/- 1.16; t = 11.270; p 
<0.001) and were more likely to rate fatigue as “always a problem” (DEP 66% vs. NoDEP 
28%; Chi Square = 62.993; df = 3; p<0.001). Therefore, fatigue scores for gender were 
analysed again in the depressed and non-depressed groups separately to exclude a possible 
gender bias due to the well-known association between female gender and depression. 
Interestingly, the gender association was evident in the non-depressed group (males 2.34+/-
2.17 vs. females 2.82 +/- 1.08; t=-3.713; p<0.001) while depressed patients presented with 
globally high AEP scores and no significant gender difference was identified for the Fatigue 
subscale (males 3.64 +/-0.543 vs. females 3.59 +/- 0.660; t=0.465; p=0.728). 
 
There was no association with the age of the patient, the epilepsy type and diagnosis, the age 
of onset and duration of the epilepsy. There was no difference between being seizure free or 
not and no difference between being on a monotherapy or on a regime with two, three, or 
more than three AEDs. However, looking at fatigue scores for individual drugs, there was a 
specific association with Levetiracetam (LEV) therapy. Fatigue categories for individual 
AEDs are shown in Figure 1. Among patients reporting fatigue as “always a problem”, most 
them were on LEV (LEV 42.3% vs. NoLEV 33.2%; Chi-Square=11.462; df=3; p=0.009). In 
addition, patients on LEV presented with higher fatigue scores (LEV = 3.0 +/- 1.0 vs. NoLEV 
= 2.7 +/- 1.2; t=2.951; p=0.003).  
To further clarify whether the observed association with LEV treatment was simply biased by 
the large number of subjects taking LEV, fatigue scores were analysed in the monotherapy 
sample (Table 2) and again most patients reporting fatigue as “always a problem” were on 
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LEV (LEV 41.7% vs. NoLEV 30.3%; Chi-Square=11.547; df = 3; p=0.009) and patients 
taking LEV presented with higher fatigue scores (LEV 3.18 +/- 0.88 vs.  NoLEV 2.64 +/- 
1.20; t = 3.355; p=0.001) as compared to those taking other AEDs in monotherapy (i.e. 
lamotrigine, valproate and carbamazepine). 
To exclude a potential confounding role of gender in the LEV group, gender distribution was 
analysed and there was no significant difference (Males on LEV 35.2% vs. Females on LEV 
37.9%; Chi-Square=0.330; df=3; p=0.616). 
To exclude a potential confounding role of depression in the association between fatigue and 
LEV treatment, the same analyses were repeated distinguishing between subjects with and 
without depression as identified with the NDDIE. As was the case in the male vs female 
subgroup analysis, the association of LEV treatment with fatigue was evident in the non-
depressed group in both the general sample and in the monotherapy sample. In fact, in the 
non-depressed general sample (n=343), most subjects rating fatigue as “always a problem” 
were on LEV (LEV 35.3% vs. NoLEV 24.1%; Chi-Square=11.180; df=3; p=0.011) and 
fatigue scores were higher in those taking LEV (LEV 2.86 +/- 1.10 vs. NoLEV 2.49 +/- 1.18; 
t=2.875; p=0.004). Similar figures were observed in the non-depressed monotherapy sample 
(n=170) (LEV 3.03 +/- 0.97 vs. NoLEV 2.44 +/- 1.19; t= 3.012; p=0.004) (Figure 2). 
As a final point, fatigue scores were compared in different AED-combinations with LEV to 
test the hypothesis that some combinations may be protective or detrimental. Analyses were 
done directly in the group of patients without depression and showed that the association with 
a sodium channel blocker (i.e. carbamazepine, oxcarbazepine, lacosamide, phenytoin) was 
not associated with high fatigue scores on LEV (Figure 3). 
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4. DISCUSSION 
 This is the first study looking specifically at fatigue as a potential AE of AED 
treatment. Our results clearly show that: i) one third of patients with epilepsy report fatigue as 
a significant problem during AED treatment; ii) it is more likely to be reported by females; 
iii) it seems to be specifically associated with LEV treatment; v) it is not mediated by an 
effect of LEV on mood. 
 
 Firstly, someone may argue that the item “tiredness” of the AEP does not necessarily 
reflect “fatigue” as a construct. In general terms, fatigue is difficult to define and measure and 
no single measure adequately captures the complexity of the phenomenon [19]. According to 
the Oxford English Dictionary “fatigue” is a synonym for “tiredness” although it is also 
inferred that fatigue is more severe. Given the paucity of data on this subject and the 
exploratory nature of our report, we found acceptable to use the item tiredness of the AEP 
before using more specific questionnaires. Our results clearly suggest the need for further 
studies on this subject using specific clinical instruments. In fact, as already stated, data on 
fatigue during AED treatment are inadequate. A review paper [14] on this subject showed 
prevalence rates for self-reported fatigue up to 33% for vigabatrin, 29% for gabapentin and 
27% for LEV and speculated on the role of GABAergic neurotransmission potentiation in 
fatigue[14]. The hypothesis that fatigue may be mediated by an imbalance between excitatory 
and inhibitory neurotransmission is further supported by data coming from multiple sclerosis 
literature suggesting an association with glutamate blockers [20]. However, the exact 
mechanism beyond central fatigue is not fully elucidated. Fatigue seems to be primarily 
mediated by inflammation in disorders like multiple sclerosis and chronic fatigue syndrome. 
It has been shown that even low levels of inflammation mediators can cause functional 
alteration in neuronal systems including the basal ganglia, anterior cingulate cortex and 
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insula, all of which can modulate aspects of central fatigue [9]. It is also noteworthy that 
neuroimmunological disorders such as multiple sclerosis and chronic fatigue syndrome are 
more common in women than men [21,22] and this is thought to be due to a combination of 
genetic susceptibility factors and hormonal differences that affect the immune system [23]. 
For all these reasons, the finding in this study of a gender bias in reported fatigue is fully in 
keeping with current literature on central fatigue but the association with LEV is more than 
intriguing and it is tempting to speculate that LEV may have a central modulatory immune 
effect that was unknown. 
Clinical trials of LEV as add-on treatment in focal epilepsies reported fatigue in up to 23% of 
patients [24]. A Cochrane review of 11 controlled add-on trials of LEV in drug-refractory 
patients showed that, despite fatigue was one of the five most common AEs, there was not an 
increased risk to develop fatigue over placebo [25]. A recently published study using the AEP 
showed that tiredness was the most common complaint in patients with epilepsy and healthy 
controls, but there was no difference between patients and controls [26]. In addition, a 
previous study comparing AEP scores in patients on monotherapy with taking CBZ, LEV, 
VPA, PHT or LTG did not show any difference in self-reported tiredness as “always a 
problem” [27]. On the other hand, a recent meta-analysis of AEs of LEV, including data from 
26 randomised controlled trials, clearly showed that fatigue is one of the AEs statistically 
significant associated with LEV. Several factors can potentially explain discrepancies among 
previous studies. First, in clinical trials, fatigue is not systematically reported and 
distinctively identified, in fact, for example, asthenia is frequently coded as a separate entry. 
Second, our study shows that the association with LEV is particularly evident when patients 
with depression are excluded. It is, therefore, possible that, even in previous studies using the 
AEP, depression may have masked differences in the reporting of tiredness between different 
groups and among different AEDs.  
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The association between LEV and fatigue in non-depressed patients is particularly intriguing. 
A recent review paper about fatigue in epilepsy pointed out that fatigue is associated with 
depression [28]. We also observed that depressed patients have higher scores for fatigue as 
compared with non-depressed ones, but this is not surprising because patients with depression 
usually present with high rates of AEs in general, especially in domains like energy levels, 
mental speed and sleep problems [29][30]. However, our results clearly point out that the 
association between fatigue and LEV is not biased by a co-existing or LEV-induced 
depressed mood, and further confirm that fatigue is a separate entity as compared to 
depression. This is entirely in keeping with current psychiatric literature on distinctive 
neuronal networks for fatigue as compared to depression, which implicate orbitofrontal areas 
as well as the anterior cingulate cortex [31]. In fact, current models of fatigue hypothesize a 
dysfunction in the non-motor areas of the basal ganglia (i.e. ventral striatum) and their 
interactions with the frontal cortex and the amygdala. The effect of LEV on these specific 
networks is currently unknown as previous neuroimaging studies focused mainly on memory  
networks [32].  
The effect of LEV on sleep can be another potential factor contributing to fatigue. An 
exploratory factor analysis of the AEP items in a large sample of patients with epilepsy 
showed that fatigue correlates with restlessness, upset stomach and disturbed sleep rather 
than with cognitive (e.g. difficulty in concentrating and memory problems) or mood items 
(depression, nervousness and aggression) [8]. An evidence-based review on the effect of 
AEDs on sleep architecture showed that LEV is a REM sleep reducer and slow-wave sleep 
enhancer in healthy subjects and becomes a slow-wave sleep reducer in patients with epilepsy 
[33]. It is quite interesting to note that the effect of LEV on sleep in patients with epilepsy has 
some similarities with classic GABAergic drugs like barbiturates which also are REM sleep 
reducers and slow-wave sleep enhancers in healthy subjects. Future studies on the 
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relationship between fatigue, AEDs and sleep are needed. 
Finally, the favourable combination between LEV and sodium channel blockers (SCB) is of 
interest. In general terms, fatigue seems to be reported less frequently with SCB than with 
GABAergic AEDs [14]. However, whether they are protective in this regard is still unknown 
and should be clearly the subject of further investigations. 
 
Our results should be considered bearing in mind the following limitations. Firstly, 
the retrospective design does not allow any clear causal relationship between LEV and 
fatigue. Secondly, the unbalanced number of patients on individual AEDs and the lack of data 
about AED dose and titration cannot support any causal relationship or dose-dependency. 
Thirdly, it is entirely possible that other AEDs, apart from LEV, are also associated with 
fatigue but they have not been identified as less frequently prescribed then LEV in our 
sample. Fourthly, it is entirely possible that other confounders, not yet identified, may 
account for the observed association between fatigue and LEV. However, the aim of our 
paper was to describe how frequently fatigue is reported by patients with epilepsy during 
AED treatment and whether specific associations warranting further studies were present. 
Our paper clearly suggests that future prospective studies on AED treatment-emergent fatigue 
are needed to clarify the magnitude of the problem and to confirm whether there is a specific 
association with LEV treatment.  
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Table 1. Clinical and demographic variables in the study sample (N = 443). 
 N (%) 
Gender 
               Male 
               Female 
 
179 (40.4%) 
264 (59.6%) 
Age, mean +/- SD 43.1 +/- 15.6 
Age at onset, mean +/- SD 24.6 +/- 17.8 
Diagnosis 
Focal 
Generalised 
Unclassified 
 
285 (64.3%) 
138 (31.1%) 
20 (4.6%) 
Seizure free 132 (29.8%) 
AED therapy 
Monotherapy 
Two AEDs 
Three AEDs 
Four AEDs 
 
213 (48.1%) 
160 (36.1%) 
52 (11.7%) 
18 (4.1%) 
AED type 
Topiramate 
Levetiracetam 
Lamotrigine 
Pregabalin 
Carbamazepine 
Oxcarbazepine 
Gabapentin 
Lacosamide 
Phenobarbital 
Phenytoin 
Valproate 
Zonisamide 
Clobazam 
 
37 (8.4%) 
163 (36.8%) 
154 (34.8%) 
15 (3.4%) 
94 (21.2%) 
16 (3.6%) 
9 (2.0%) 
19 (4.3%) 
8 (1.8%) 
30 (6.8%) 
71 (16%) 
13 (2.9%) 
41 (9.3%) 
Total n AED failed, mean +/- SD 3.2 +/- 2.3 
Fatigue 
Never a problem 
Rarely a problem 
Sometimes a problem 
Always a problem 
 
96 (21.7%) 
40 (9%) 
145 (32.7%) 
162 (36.6%) 
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Table 2. Antiepileptic drugs in monotherapy. 
 
 
 
 
 
 
 
  
Drug N = 213 
Topiramate 
Levetiracetam 
Lamotrigine 
Carbamazepine 
Oxcarbazepine 
Gabapentin 
Phenytoin 
Valproate 
Clonazepam 
5 (2.3%) 
48 (22.5%) 
83 (39%) 
36 (16.9%) 
3 (1.4%) 
3 (1.4%) 
5 (2.3%) 
29 (13.6%) 
1 (0.5%) 
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Figure 1. Distribution of Fatigue item scores as presented in the Adverse Event Profile.  
 
Figure 2. Fatigue scores in patients taking levetiracetam (LEV) as compared with the 
remaining subjects in the total and monotherapy samples with or without depression 
(DEP).   
* t=2.951; p=0.003 **t=2.875 p=0.004  #t = 3.355 p =0.001  ##t= 3.012; p=0.004 
 
Figure 3. Percentage of patients reporting fatigue as “always a problem” in patients 
with or without levetiracetam (LEV) in combination with sodium channel blockers 
(NaCB). 
*Chi Square 13.134 df=3 p=0.004 
 
 
 
 
 
 
 
 
 
